Banzel (rufinamide)

What is Rufinamide, and how does it work?

Rufinamide tablets are a prescription medicine used with other medicines to treat seizures associated with Lennox- Gastaut Syndrome (LGS) in adults and pediatric patients 1 year of age and older. It is not known if rufinamide tablets are safe and effective in the treatment of Lennox-Gastaut Syndrome in pediatric patients under 1 year of age.

What are the side effects of Rufinamide?

Rufinamide tablets may cause serious side effects
including:

Rufinamide tablets can also cause allergic reactions or
serious problems which may affect organs and other parts of your body like the
liver or blood cells. You may or may not have a rash with these types of
reactions.

Call your healthcare provider right away if you have
any of the following. Symptoms may include:

swelling of your face, eyes, lips, or tongue
trouble swallowing or breathing
a skin rash
hives
fever, swollen glands, or sore throat that do not go away
or come and go
swollen glands
yellowing of your skin or eyes
dark urine
unusual bruising or bleeding
severe fatigue or weakness
severe muscle pain
your seizures happen more often or become worse

Call your healthcare provider right away if you have any
of the symptoms listed above.

The most common side effects of rufinamide tablets
include:

Tell your healthcare provider about any side effect that
bothers you or that does not go away. These are not all of the possible side
effects of rufinamide tablets. For more information, ask your healthcare
provider or pharmacist.

Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Rufinamide?

Pediatric Patients (1 Year to Less Than 17 Years)

The recommended starting daily dose of rufinamide in pediatric patients with Lennox-Gastaut Syndrome is approximately 10 mg/kg administered in two equally divided doses.
The dose should be increased by approximately 10 mg/kg increments every other day until a maximum daily dose of 45 mg/kg, not to exceed 3,200 mg, administered in two equally divided doses, is reached.
It is not known whether doses lower than the target doses are effective.

Adults (17 Years and Older)

The recommended starting daily dose of rufinamide in adults with Lennox-Gastaut Syndrome is 400 mg per day to 800 mg per day administered in two equally divided doses.
The dose should be increased by 400 mg to 800 mg every other day until a maximum daily dose of 3200 mg, administered in two equally divided doses, is reached. It is not known whether doses lower than 3,200 mg are effective.

Administration Information

Administer rufinamide with food. Rufinamide film-coated tablets can be administered whole, as half tablets or crushed.

Dosing In Patients Undergoing Hemodialysis

Hemodialysis may reduce exposure to a limited (about 30%) extent. Accordingly, adjusting the rufinamide dose during the dialysis process should be considered.

Dosing In Patients With Hepatic Disease

Use of rufinamide in patients with hepatic impairment has not been studied.
Therefore, use in patients with severe hepatic impairment is not recommended. Caution should be exercised in treating patients with mild to moderate hepatic impairment.

Dosing In Patients Taking Valproate

Patients taking valproate should begin rufinamide at a dose lower than 10 mg/kg per day in pediatric patients or 400 mg per day in adults.

What drugs interact with Rufinamide?

Effects Of Rufinamide On Other AEDs

Population pharmacokinetic analysis of average
concentration at steady state of carbamazepine, lamotrigine. phenobarbital,
phenytoin, topiramate, and valproate showed that typical rufinamide Cmax levels
had little effect on the pharmacokinetics of other AEDs. Any effects, when they
occur, have been more marked in the pediatric population.

Table 6 summarizes the drug-drug interactions of
rufinamide with other AEDs.

Table 6: Summary of drug-drug interactions of
rufinamide with other antiepileptic drugs

AED Co- administered
Influence of Rufinamide on AED concentration^a
Influence of AED on Rufinamide concentration

Carbamazepine
Decrease by 7 to 13%^b
Decrease by 19 to 26% Dependent on dose of carbamazepine

Lamotrigine
Decrease by 7 to 13%^b
No Effect

Phenobarbital
Increase by 8 to 13% ^b
Decrease by 25 to 46%^c,dIndependent of dose or concentration of phenobarbital

Phenytoin
Increase by 7 to 21%^b
Decrease by 25 to 46%^c,dIndependent of dose or concentration of phenytoin

Topiramate
No Effect
No Effect

Valproate
No Effect
Increase by < 16 to 70%^cDependent on concentration of valproate

Primidone
Not Investigated
Decrease by 25 to 46%^c,dIndependent of dose or concentration of primidone

Benzodiazepines^e
Not Investigated
No Effect

^a Predictions are based on rufinamide
concentrations at the maximum recommended dose of rufinamide.
^b Maximum changes predicted to be in pediatric patients and in adult
patients who achieve significantly higher levels of rufinamide, as the effect
of rufinamide on these AEDs is concentration-dependent.
^c Larger effects in pediatric patients at high doses/concentrations
of AEDs.
^d Phenobarbital, primidone and phenytoin were treated as a single
covariate (phenobarbital-type inducers) to examine the effect of these agents
on rufinamide clearance.
^e All compounds of the benzodiazepine class were pooled to examine
for ‘class effect’ on rufinamide clearance.

Phenytoin: The decrease in clearance of phenytoin
estimated at typical levels of rufinamide (Cavss 15µg/mL) is predicted to increase
plasma levels of phenytoin by 7 to 21%. As phenytoin is known to have
non-linear pharmacokinetics (clearance becomes saturated at higher doses), it
is possible that exposure will be greater than the model prediction.

Effects Of Other AEDs On Rufinamide

Potent cytochrome P450 enzyme inducers, such as
carbamazepine, phenytoin, primidone, and phenobarbital, appear to increase the
clearance of rufinamide (see Table 6).
Given that the majority of clearance of
rufinamide is via a non- CYP-dependent route, the observed decreases in blood
levels seen with carbamazepine, phenytoin, phenobarbital, and primidone are
unlikely to be entirely attributable to induction of a P450 enzyme.
Other
factors explaining this interaction are not understood. Any effects, where they
occurred, were likely to be more marked in the pediatric population.

Valproate

Patients stabilized on rufinamide before being prescribed
valproate should begin valproate therapy at a low dose, and titrate to a
clinically
effective dose.
Similarly, patients on valproate should begin at a rufinamide dose lower
than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults).

Effects Of Rufinamide On Hormonal Contraceptives

Female patients of childbearing age should be warned that the concurrent
use of rufinamide with hormonal contraceptives may renderthis method of
contraception less effective.
Additional non-hormonal forms of contraception are recommended when
using rufinamide.

Latest Neurology News

Trending on MedicineNet

Is Rufinamide safe to use while pregnant or breastfeeding?

There are no adequate and well-controlled studies in pregnant women.
Rufinamide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Rufinamide produced developmental toxicity when administered orally to pregnant animals at clinically relevant doses.
Rufinamide is likely to be excreted in human milk.
Because of the potential for serious adverse reactions in nursing infants from rufinamide, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.